background
studi
examin
contribut
airway
inflamm
delay
lung
function
recoveri
occur
peopl
follow
virusinduc
asthma
exacerb
method
subject
n
recruit
hospit
admiss
acut
asthma
exacerb
respiratori
viru
infect
diagnos
viral
nucleic
acid
detect
andor
cell
cultur
use
induc
sputum
nasal
throat
swab
data
collect
includ
lung
function
answer
common
cold
asthma
control
questionnair
induc
sputum
cellular
profil
subject
reexamin
week
postexacerb
compar
stabl
asthmat
subject
n
recruit
ambulatori
care
clinic
result
persist
airway
obstruct
defin
lung
function
improv
followup
ie
chang
fev
percent
predict
fev
observ
subject
airway
recoveri
fev
observ
remain
subject
subject
acut
episod
airwayrecoveri
group
increas
total
cell
count
p
increas
number
neutrophil
p
increas
percentag
neutrophil
p
compar
group
stabl
subject
asthma
postexacerb
airwayrecoveri
group
reduc
number
neutrophil
increas
percentag
eosinophil
contrast
exacerb
subject
persist
airway
obstruct
show
differ
inflammatori
cell
count
compar
stabl
subject
asthma
cell
count
chang
postexacerb
symptom
improv
group
postexacerb
howev
persistentairwayobstruct
group
asthma
remain
uncontrol
conclus
persist
airway
obstruct
uncontrol
asthma
observ
peopl
viral
asthma
exacerb
abnorm
associ
inflammatori
cell
influx
airway
line
fluid
exacerb
may
reflect
involv
noncellular
element
work
explor
mechan
lead
incomplet
airway
recoveri
chest
abbrevi
acq
asthma
control
questionnair
ccq
common
cold
questionnair
ecp
eosinophil
cation
protein
ev
enteroviru
fev
chang
fev
percent
predict
ic
inhal
corticosteroid
il
interleukin
iqr
interquartil
rang
mpv
metapneumoviru
pcr
polymeras
chain
reaction
pef
peak
expiratori
flow
rsv
respiratori
syncyti
viru
rv
rhinoviru
origin
research
asthma
wwwchestjournalorg
chest
ever
exacerb
asthma
respons
larg
burden
ill
australia
throughout
world
viral
infect
main
caus
asthma
exacerb
requir
hospit
respiratori
virus
isol
patient
asthma
exacerb
requir
hospit
adult
children
mechan
drive
viral
asthma
exacerb
clearli
differ
wellcharacter
pathogenesi
allergeninduc
asthma
driven
interleukin
il
eosinophil
infiltr
viral
asthma
exacerb
involv
mark
neutrophil
infiltr
togeth
eosinophil
degranul
chemokin
rant
regul
activ
normal
cell
express
secret
promot
eosinophil
degranul
cytokin
suppress
eosinophil
cellular
infiltr
may
import
inflammatori
respons
gene
express
mediat
upregul
patient
virusinduc
asthma
despit
optim
medic
therapi
incomplet
recoveri
airway
function
occur
rel
high
proport
peopl
acut
asthma
exacerb
corn
et
al
observ
peopl
asthma
infect
human
rhinoviru
rv
lower
respiratori
tract
symptom
experienc
often
sever
longer
durat
nonasthmat
peopl
persist
lower
respiratori
symptom
peopl
asthma
extend
day
well
beyond
expect
durat
common
cold
symptom
chang
et
al
describ
group
prolong
episod
persist
asthma
last
month
year
trigger
symptom
viral
infect
case
incomplet
recoveri
peak
expiratori
flow
pef
also
report
acut
episod
asthma
anoth
studi
trend
asthmat
subject
human
rv
infect
lower
pef
measur
convalesc
delay
recoveri
lung
function
also
report
follow
copd
exacerb
subject
recov
baselin
pef
level
week
thu
persist
airway
abnorm
respiratori
exacerb
welldocu
clinic
problem
occur
patient
asthma
copd
addit
delay
recoveri
lung
function
acut
asthma
episod
inflammatori
respons
shown
persist
pizzichini
et
al
studi
adult
experienc
asthma
exacerb
trigger
viral
infect
n
vs
trigger
nonvir
caus
n
observ
persist
reduct
fev
vs
predict
respect
persist
sputum
neutrophilia
vs
cell
respect
followup
virusinfect
group
elradhi
et
al
report
persist
elev
serum
solubl
eosinophil
cation
protein
ecp
oral
corticosteroid
treatment
acut
asthma
children
hypothes
delay
recoveri
lung
function
acut
asthma
episod
may
due
alter
inflammatori
respons
aim
studi
elucid
role
airway
inflamm
persist
airway
obstruct
occur
peopl
follow
virusinduc
asthma
exacerb
care
character
subject
whose
condit
improv
follow
virusinduc
asthma
exacerb
compar
airway
inflammatori
profil
subject
improv
postexacerb
patient
admit
john
hunter
hospit
newcastl
nsw
australia
experienc
acut
exacerb
asthma
recruit
studi
februari
may
subset
patient
previous
describ
induc
sputum
sampl
collect
ultrason
nebul
isoton
salin
solut
previous
describ
select
criteria
presenc
acut
asthma
posit
viral
infect
age
year
fev
predict
complet
followup
visit
subject
studi
week
postexacerb
particip
provid
nasalthroat
swab
underw
skin
allergen
test
spirometri
particip
also
complet
common
cold
questionnair
ccq
asthma
control
questionnair
acq
acq
sevenitem
questionnair
valid
measur
goal
asthma
manag
ie
minim
daytim
nighttim
symptom
activ
limit
agonist
use
bronchoconstrict
analysi
asthma
statu
use
score
system
determin
wellcontrol
asthma
optim
cut
point
score
indic
inadequ
control
asthma
followup
subject
categor
one
follow
two
group
persistentairwayobstruct
group
defin
subject
improv
lung
function
ie
chang
fev
percent
predict
fev
airwayrecoveri
group
defin
fev
stabl
subject
asthma
recruit
within
studi
period
includ
comparison
group
met
american
thorac
societi
criteria
asthma
diagnosi
experienc
chang
asthma
activ
respiratori
infect
last
week
recruit
john
hunter
hospit
ambulatori
care
clinic
written
inform
consent
obtain
particip
studi
approv
hunter
area
health
servic
univers
newcastl
human
research
ethic
committe
select
portion
induc
sputum
sampl
alloc
lytic
solut
buffer
rlt
qiagen
hilden
germani
rna
extract
subsequ
messeng
rna
express
analysi
viru
polymeras
chain
reaction
pcr
vitro
cultur
viruspermiss
human
epitheli
cell
line
hel
outgrowth
respiratori
virus
sequenti
dithiothreitol
phosphatebuff
salin
solut
cellular
dispers
profil
involv
select
sputum
sampl
saliva
process
dithiothreitol
solut
filter
dispers
suspens
perform
total
cell
count
leukocyt
cytospin
also
prepar
stain
nwald
giemsa
stain
differenti
cell
count
obtain
nonsquam
cell
nasal
swab
throat
swab
also
immers
lytic
solut
buffer
rlt
qiagen
extract
purif
sputum
sampl
clarif
vitro
cultur
supernat
swab
rna
perform
use
standard
commerci
avail
kit
rneasi
kit
qiagen
per
instruct
manufactur
rna
reversetranscrib
total
complementari
dna
use
random
primer
standard
commerci
avail
kit
superscript
ii
rt
kit
invitrogen
carlsbad
ca
patient
sampl
assay
presenc
rv
enteroviru
ev
influenza
viru
type
b
respiratori
syncyti
viru
rsv
type
b
nonsever
acut
respiratori
syndrom
coronaviru
metapneumoviru
mpv
viru
rna
transcript
due
applic
advanc
realtim
pcr
technolog
initi
gelbas
pcr
assay
rv
ev
rsv
mpv
replac
realtim
pcr
assay
taqman
probe
appli
biosystem
foster
citi
ca
rv
ev
rsv
type
b
human
mpv
coronaviru
later
stage
studi
realtim
pcr
also
use
confirm
prior
gelbas
viral
detect
result
pcr
assay
taqman
appli
biosystem
proceed
use
complementari
dna
product
commerci
avail
kit
realmastermix
probe
rox
kit
eppendorf
ag
hamburg
germani
cycl
paramet
name
min
activ
pcr
assay
hotmast
taq
dna
pcr
eppendorf
ag
cycl
follow
min
abi
cycler
appli
biosystem
foster
citi
ca
subject
consid
posit
viru
presenc
viru
determin
either
direct
molecular
detect
ie
gel
pcr
realtim
pcr
sputum
swab
nasal
throat
saliva
specimen
postcel
cultur
molecular
detect
gel
pcr
realtim
pcr
sputum
saliva
specimen
subject
virusposit
acut
asthma
visit
classifi
visit
accord
improv
fev
liter
persist
airway
obstruct
airway
recoveri
respect
analysi
perform
use
statist
softwar
packag
stata
version
stata
corpor
colleg
station
tx
result
present
median
interquartil
rang
iqr
signific
p
determin
nonparametr
kruskalw
test
fisher
exact
test
test
post
hoc
analysi
appli
signific
variabl
use
kruskalw
test
test
stata
corpor
pair
analys
chang
visit
visit
conduct
use
wilcoxon
sign
rank
test
virus
detect
subject
acut
exacerb
virus
includ
follow
rv
subject
ev
subject
influenza
viru
type
subject
influenza
viru
type
b
subject
rsv
subject
eleven
subject
dual
virus
subject
test
posit
three
virus
follow
acut
exacerb
persistentairwayobstruct
observ
subject
airway
recoveri
observ
subject
characterist
group
describ
tabl
signific
differ
atopi
group
howev
persistentairwayobstruct
group
use
significantli
higher
mainten
dose
inhal
corticosteroid
ic
preexacerb
longer
durat
asthma
detail
acut
asthma
episod
persistentairwayobstruct
group
compar
airwayrecoveri
group
describ
tabl
examin
emerg
depart
fig
airwayrecoveri
group
highli
signific
fev
result
valu
recoveri
similar
stabl
subject
asthma
persistentairwayobstruct
group
howev
fev
percent
predict
improv
airwayrecoveri
group
ccq
acq
score
show
highli
signific
improv
visit
valu
similar
stabl
subject
asthma
persistentairwayobstruct
group
improv
ccq
acq
score
howev
asthma
continu
uncontrol
postexacerb
visit
subject
persistentairwayobstruct
group
similar
inflammatori
cell
profil
stabl
subject
asthma
contrast
airwayrecoveri
group
increas
total
cell
count
fig
top
neutrophil
count
fig
bottom
b
compar
stabl
subject
asthma
recoveri
neutrophil
count
airwayrecoveri
group
decreas
significantli
tabl
contrast
subject
persistentairwayobstruct
group
show
signific
decreas
inflammatori
cell
count
postexacerb
persist
airway
obstruct
follow
acut
asthma
exacerb
signific
clinic
problem
approxim
one
four
peopl
recov
sever
asthma
exacerb
viru
infect
experi
minim
improv
lung
function
continu
experi
persist
airway
obstruct
poor
asthma
control
studi
first
examin
role
lower
airway
inflamm
phenomenon
determin
subject
persist
airway
obstruct
follow
viru
exacerb
time
exacerb
level
total
inflammatori
cell
eosinophil
macrophag
lymphocyt
airway
similar
stabl
subject
asthma
furthermor
inflammatori
cell
profil
lower
airway
individu
chang
postexacerb
despit
improv
symptom
clinic
import
group
despit
absenc
inflammatori
cell
influx
airway
exacerb
asthma
symptom
uncontrol
exacerb
although
symptom
improv
week
postexacerb
continu
uncontrol
airwayrecoveri
persistentairwayobstruct
group
experienc
acut
asthma
exacerb
appar
similar
sever
tabl
two
group
clinic
differ
followup
tabl
indic
exacerb
ccq
elev
airwayrecoveri
persistentairwayobstruct
group
week
postexacerb
similar
improv
viru
symptom
seen
group
percentag
chang
ccq
fig
tabl
also
describ
inadequ
asthma
control
exacerb
airwayrecoveri
persistentairwayobstruct
group
indic
asthma
control
score
howev
highli
signific
improv
acq
score
airwayrecoveri
group
demonstr
wellcontrol
asthma
acq
score
visit
modest
improv
seen
person
persistentairwayobstruct
group
continu
inadequ
control
asthma
acq
score
postexacerb
poor
lung
function
percent
predict
fev
observ
acut
episod
significantli
improv
airwayrecoveri
group
valu
return
level
stabl
asthma
patient
postexacerb
howev
signific
valu
given
median
iqr
unless
otherwis
indic
compar
stabl
subject
asthma
subject
asthma
n
wwwchestjournalorg
chest
februari
improv
fev
persistentairwayobstruct
group
fig
tabl
thu
two
group
clinic
similar
exacerb
distinctli
differ
recoveri
may
reflect
differ
group
result
viral
infect
due
design
studi
preexacerb
data
avail
howev
higher
dose
mainten
icss
use
persistentairwayobstruct
group
suggest
group
sever
ill
exacerb
possibl
may
preexist
airflow
obstruct
incomplet
clinic
recoveri
exacerb
report
previous
copd
patient
patient
experienc
exacerb
recov
baselin
lung
function
week
seemung
et
al
relat
exacerb
length
magnitud
acut
deterior
extent
acut
deterior
assess
studi
design
data
tabl
suggest
acut
episod
similar
sever
two
group
anoth
longitudin
studi
copd
patient
found
time
clinic
recoveri
baselin
level
fev
symptom
exacerb
took
longer
mechan
recoveri
rate
slow
time
unclear
suggest
may
associ
postvir
increas
airway
system
inflamm
data
indic
subject
persistentairwayobstruct
group
longer
durat
asthma
group
follow
longer
time
return
baselin
fev
may
eventu
observ
altern
studi
design
allow
assess
airflow
obstruct
preexacerb
would
requir
test
hypothesi
asthma
exacerb
airwayrecoveri
group
show
elev
total
inflammatori
cell
count
driven
increas
number
neutrophil
fig
decreas
postexacerb
tabl
consist
known
effect
viral
infect
airway
convers
patient
persistentairwayobstruct
group
show
lower
airway
inflammatori
profil
exacerb
similar
stabl
asthma
fig
chang
significantli
postexacerb
tabl
surpris
consid
wellestablish
role
neutrophil
drive
innat
immun
respons
viral
infect
howev
appar
insensit
lower
airway
inflamm
presenc
viru
suggest
suppress
innat
immun
respons
subject
persistentairwayobstruct
group
use
higher
mainten
dose
icss
airwayrecoveri
group
tabl
possibl
high
dose
icss
may
inhibit
gener
inflammatori
mediat
tumor
necrosi
therebi
prevent
infiltr
inflammatori
cell
airway
number
mechan
associ
viral
infect
may
lead
persist
abnorm
lung
function
poor
asthma
control
postexacerb
depend
inflammatori
cell
influx
virusinduc
eosinophil
activ
may
increas
releas
mediat
ecp
leukotrien
may
worsen
asthma
symptom
activ
eosinophil
may
also
drive
neurogen
inflamm
releas
eosinophil
major
basic
protein
endogen
antagonist
muscarin
receptor
receptor
normal
inhibit
releas
acetylcholin
block
major
basic
protein
acetylcholin
releas
result
airway
muscl
hyperrespons
viral
induct
vascular
leakag
also
report
mediat
ecp
exud
airway
lumen
may
sustain
perpetu
inflammatori
process
viral
activ
mast
cell
lead
increas
histamin
releas
may
also
contribut
worsen
asthma
mucu
hypersecret
also
link
viral
infect
thu
rang
differ
virusinduc
mechan
may
exacerb
varieti
physiolog
featur
character
asthma
involv
infiltr
lower
airway
inflammatori
cell
final
possibl
exacerb
persistentairwayobstruct
group
driven
upper
rather
lower
airway
inflamm
support
data
tabl
indic
minim
chang
asthma
symptom
visit
support
observ
throat
symptom
one
domain
show
greatest
improv
postexacerb
conclus
observ
approxim
one
four
peopl
asthma
continu
persist
airway
obstruct
uncontrol
asthma
symptom
week
postvir
asthma
exacerb
thoroughli
describ
phenomenon
determin
involv
influx
inflammatori
cell
lower
airway
mechan
activ
resid
airway
cell
enhanc
upper
airway
inflamm
explor
number
peopl
experi
persist
airway
obstruct
postexacerb
repres
signific
proport
asthmat
patient
peopl
follow
postexacerb
continu
uncontrol
asthma
lead
signific
loss
qualiti
life
acknowledg
assist
collect
sampl
clinic
data
receiv
naomi
timmin
tabl
